ATE529530T1 - Rekombinante antikörper zum nachweis und zur neutralisierung von milzbrandtoxin - Google Patents

Rekombinante antikörper zum nachweis und zur neutralisierung von milzbrandtoxin

Info

Publication number
ATE529530T1
ATE529530T1 AT02789453T AT02789453T ATE529530T1 AT E529530 T1 ATE529530 T1 AT E529530T1 AT 02789453 T AT02789453 T AT 02789453T AT 02789453 T AT02789453 T AT 02789453T AT E529530 T1 ATE529530 T1 AT E529530T1
Authority
AT
Austria
Prior art keywords
antenracy
toxin
neutralization
detection
recombinant antibodies
Prior art date
Application number
AT02789453T
Other languages
English (en)
Inventor
George Georgiou
B L Iverson
J A Maynard
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of ATE529530T1 publication Critical patent/ATE529530T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1278—Bacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM
    • Y10S530/864—Monoclonal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM
    • Y10S530/864—Monoclonal
    • Y10S530/865—Human
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT02789453T 2001-11-05 2002-11-05 Rekombinante antikörper zum nachweis und zur neutralisierung von milzbrandtoxin ATE529530T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33284901P 2001-11-05 2001-11-05
PCT/US2002/035567 WO2003040384A1 (en) 2001-11-05 2002-11-05 Recombinant antibodies for the detection and neutralization of anthrax toxin

Publications (1)

Publication Number Publication Date
ATE529530T1 true ATE529530T1 (de) 2011-11-15

Family

ID=23300112

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02789453T ATE529530T1 (de) 2001-11-05 2002-11-05 Rekombinante antikörper zum nachweis und zur neutralisierung von milzbrandtoxin

Country Status (7)

Country Link
US (1) US7446182B1 (de)
EP (1) EP1451338B8 (de)
JP (1) JP2005508395A (de)
AT (1) ATE529530T1 (de)
AU (1) AU2002354047B2 (de)
CA (1) CA2465891C (de)
WO (1) WO2003040384A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2526398C (en) * 2003-05-21 2014-07-15 Medarex, Inc. Human monoclonal antibodies against bacillus anthracis protective antigen
GB0312642D0 (en) * 2003-06-03 2003-07-09 Secr Defence Pharmaceutical composition
US20100003276A1 (en) * 2004-12-07 2010-01-07 Hermes Jeffery D Methods for treating anthrax and inhibiting lethal factor
WO2007084107A2 (en) 2004-12-22 2007-07-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that neutralize anthrax protective antigen (pa) toxin
WO2007123562A2 (en) * 2005-07-22 2007-11-01 Genexel-Sein, Inc. Anthrax therapies, compositions, and methods related thereto
US8663926B2 (en) 2006-02-15 2014-03-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention Detection of anthrax pathogenicity factors
AU2007349310B2 (en) 2006-06-30 2013-03-14 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS OF DISEASE CONTROL AND PREVENTION (WASHINGTON D.C.) Anthrax carbohydrates,synthesis and uses thereof
US8420607B2 (en) * 2006-06-30 2013-04-16 University Of Georgia Research Foundation, Inc. Anthrax carbohydrates, synthesis and uses thereof
WO2009154461A1 (en) * 2008-06-19 2009-12-23 Prothix Bv Use of anti-factors xi antibodies for prevention of thrombus formation
NZ597580A (en) * 2009-07-20 2013-11-29 Univ Nat Taiwan Polypeptides selective for alpha.v.beta.3 integrin conjugated with a variant of human serum albumin (hsa) and pharmaceutical uses thereof
CN106198972A (zh) * 2016-08-30 2016-12-07 盐城卫生职业技术学院 一种检测与筛选产毒素菌的原位免疫方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5601823A (en) * 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6329156B1 (en) * 1999-03-22 2001-12-11 The Regents Of The University Of California Method for screening inhibitors of the toxicity of Bacillus anthracis
US6916474B2 (en) * 2002-07-15 2005-07-12 Board Of Regents, The University Of Texas System Antibodies with increased affinities for anthrax antigens
CA2526398C (en) 2003-05-21 2014-07-15 Medarex, Inc. Human monoclonal antibodies against bacillus anthracis protective antigen

Also Published As

Publication number Publication date
EP1451338A1 (de) 2004-09-01
EP1451338A4 (de) 2006-12-27
EP1451338B1 (de) 2011-10-19
AU2002354047B2 (en) 2007-11-22
JP2005508395A (ja) 2005-03-31
CA2465891A1 (en) 2003-05-15
WO2003040384A1 (en) 2003-05-15
US7446182B1 (en) 2008-11-04
US20080262204A1 (en) 2008-10-23
EP1451338B8 (de) 2012-05-02
CA2465891C (en) 2012-05-15

Similar Documents

Publication Publication Date Title
PH12021550793A1 (en) Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments
FR2794865B1 (fr) Methode de detection precoce des flavivirus et ses applications
DK1636561T3 (da) Kombinatorisk proteinbiblioteksscreening ved hjælp af periplasmatisk ekspression
DE60230029D1 (de) Immunisierungstherapie zur behandlung von atherosklerose
DE60236965D1 (de) Coronavirus-ähnliche partikel enthaltende funktionell deletierte genome
ATE549347T1 (de) Gene von säugetiere, und damit verbundene reagentien, methoden
DE69823985D1 (de) Nachweis der krankheitsbedingten konformation eines proteins
WO2003048337A3 (en) Antibody to latent membrane proteins and uses thereof
DE602005013670D1 (de) Zusammensetzungen und verfahren zur quantifizierung von serumglykoproteinen
ATE417275T1 (de) Puffern zur stabilizierung von hcv antigenen
BR0207068A (pt) Anticorpo monoclonal para a protéina clfa, anti-soro isolado, anticorpo isolado e anticorpo humanizado contendo o referido anticorpo, kit diagnóstico compreendendo o referido anticorpo, método para diagnóstico de uma infecção por s.aureus, composição farmacêutica para o tratamento ou prevenção da referida infecção, método para indução de de uma resposta imunológica, método para identificação de anticorpos monoclonais para a protéina clfa e fragmento ativo isolado a partir do domìnio a da protéina clfa do s.aureus
DK1292328T3 (da) Kimære humant papillomvirus- (HPV) - molekyler og deres anvendelse
DK1887014T3 (da) Humane Toll-homologer
ATE440860T1 (de) An proteinphosphatase 2a bindende synthetische oder natürliche peptide, identifikationsverfahren und anwendungen
EP1451338B8 (de) Rekombinante antikörper zum nachweis und zur neutralisierung von milzbrandtoxin
ATE426172T1 (de) Zusammensetzungen und verfahren zum nachweis von ehrlichia canis- und ehrlichia chaffeensis- antikírpern
EP1395275A4 (de) Beta-secretase-substrate und ihre verwendung
EP1411962A4 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
DE50015629D1 (de) Verwendung cd28 spezifischer monoklonaler antikörpsetzung zur behandlung von virusinfektionen
ATE425187T1 (de) Materialien und methoden zur behandlung von hepatitis c
DE602004028592D1 (de) Gegen clostridium difficile gerichtete antikörper
ATE389881T1 (de) Detektion von kleinen molekülen mit piezo- elektrischem sensor
EP1308730A4 (de) Verfahren zum nachweis oder zum bestimmen von hbv
ATE527280T1 (de) Fluoreszentprotein und chromoprotein
DE60208534D1 (de) Verwendung von antikörper gegen mag zur behandlung ischämischer schlaganfälle

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties